In vitro chemosensitivity test of glioma cells and ultrastructural changes in tissue culture
XU Lixin1, ZHANG Wei2, SHI Zhongfang1, DONG Liping1, YAN Xu1, and YUAN Fang1
1.Department of Pathophysiology, Beijing Neurosurgical Institute,Beijing Tiantan Hospital.Capital Medical Unirersity,Beijing 100050,China; 2. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China
Abstract： Objective To select chemotherapeutic agents based on in vitro chemosensitivity test of glioma in tissue culture in order to provide experimental data for individualized treatment of glioma.Methods One hundred and twelve specimens resected from brain glioma were used to evaluate the in vitro chemosensitivity of glioma with tissue culture. Six chemotherapeutic agent groups against brain cancer were designed, which were nimustine (ACNU), cisplatin (DDP), temozolomide (TMZ) , vincristine (VCR), teniposide (VM26) and DDP＋VM26. The ultrastructural changes of brain glioma after exposure to chemotherapeutic agents were observed under an electron microscope. Furthermore, the correlations between drug chemosensitivity and patients’ pathological grade were analyzed.Results The chemosensitivity of DDP＋VM26 group and VM26 group was significantly higher than that of the other four groups (P＜0.003). Under an electron microscope, the glioma cells showed apoptosis and necrosis changes after exposure to chemotherapeutic agents. The chemosensitivity of DDP＋VM26 group was correlated with the pathological grade of patients (χ2=4.447, P=0.035).Conclusions The sensitivity of patients with different glioma to chemotherapeutic drugs is different, and the apoptosis or necrosis of tumor cells may be one of the mechanisms of chemotherapeutic drugs.
徐立新,张伟,师忠芳,董丽萍,闫旭,袁芳. 人脑胶质瘤培养组织对化疗药物的敏感性[J]. 武警医学, 2018, 29(7): 660-659.
XU Lixin, ZHANG Wei, SHI Zhongfang, DONG Liping, YAN Xu, and YUAN Fang. In vitro chemosensitivity test of glioma cells and ultrastructural changes in tissue culture. Med. J. Chin. Peop. Armed Poli. Forc., 2018, 29(7): 660-659.
Singh B, Li R, Xu L, et al. Prediction of survival in patients with head and neck cancer using the histoculture drug response assay [J]. Head Neck, 2002, 24(5): 437-442.
Batash R, Asna N, Schaffer P, et al. Glioblastoma multiforme, diagnosis and treatment; recent literature review[J]. Curr Med Chem, 2017, 24(27):3002-3009.
[6]
Furukawa T, Kubota T, Hoffman R M. Clinical applications of the histoculture drug response assay[J]. Clin Cancer Res, 1995,1(3):305-311.
Anjum K, Shagufta B I, Abbas S Q, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: a review[J]. Biomed Pharmacother, 2017, 92: 681-689.
2018, Vol. 29 
